Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.110
+0.020 (1.83%)
At close: May 16, 2025, 4:00 PM
1.120
+0.010 (0.90%)
After-hours: May 16, 2025, 6:58 PM EDT
Allogene Therapeutics Employees
As of December 31, 2024, Allogene Therapeutics had 229 total employees, including 226 full-time and 3 part-time employees. The number of employees decreased by 4 or -1.72% compared to the previous year.
Employees
229
Change (1Y)
-4
Growth (1Y)
-1.72%
Revenue / Employee
n/a
Profits / Employee
-$1,101,847
Market Cap
242.79M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AbbVie | 55,000 |
Eli Lilly and Company | 47,000 |
PT Medikaloka Hermina Tbk | 17,626 |
PT Siloam International Hospitals Tbk | 14,616 |
PT Kalbe Farma Tbk. | 12,903 |
PT Mitra Keluarga Karyasehat Tbk | 8,803 |
Samsung Biologics | 4,770 |
PT Sejahteraraya Anugrahjaya Tbk | 4,148 |
ALLO News
- 3 days ago - Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 10 days ago - Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 23 days ago - Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - GlobeNewsWire
- 2 months ago - Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - GlobeNewsWire